0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ODYSSEY Polymer.. (DB RCT) -36% 1.36 [0.70-2.61] death 16/69 13/76 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Late treatment -36% 1.36 [0.70-2.61] 16/69 13/76 36% higher risk All studies -36% 1.36 [0.70-2.61] 16/69 13/76 36% higher risk 1 tradipitant COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Effect extraction pre-specified(most serious outcome) Favors tradipitant Favors control
Tradipitant is an oral small-molecule neurokinin-1 receptor antagonist that blocks substance P signalling, potentially reducing neurogenic pulmonary inflammation.
Apr 1
2024
 Polymeropoulos et al., NCT04326426 ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection
36% higher mortality (p=0.41) and no change in improvement. RCT 145 severe/critical COVID-19 patients in the USA, showing no significant difference with tradipitant treatment.